NCT01688739View on ClinicalTrials.gov

Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

March 13, 2012

Primary Completion Date

March 27, 2013

Study Completion Date

March 27, 2013

Conditions

Migraine

Interventions

DRUG

Erenumab

Administered by subcutaneous injection or intravenous injection

DRUG

Placebo

Administered by subcutaneous injection or intravenous injection

Trial Locations (1)

3000

Research Site, Leuven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT01688739 - Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients | Biotech Hunter | Biotech Hunter